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Abstract
Background:  Cervical cancer is one of the most important cancers in African women.
Polymorphisms in the Fas (FasR) and Fas ligand (FasL) genes have been reported to be associated
with cervical cancer in certain populations. This study investigated whether these polymorphisms
are associated with cervical cancer or human papillomavirus (HPV) infection in South African
women.
Findings: Participants were 447 women with invasive cervical cancer (106 black African and 341
women of mixed-ancestry) and 424 healthy women controls, matched by age, (101 black African
and 323 women of mixed-ancestry) and domicile (rural or urban). Two polymorphisms in Fas gene
(FasR-1377G/A, FasR-670A/G) and one in FasL gene (FasL844T/C) were genotyped by TaqMan.
None of the polymorphisms, or the Fas haplotypes, showed a significant association with cervical
cancer. There was also no association with HPV infection in the control group. However, on
analysis of the control group, highly significant allele, genotype and haplotype differences were
found between the two ethnic groups. There were generally low frequencies of FasR-1377A alleles,
FasR-670A alleles and FasL-844C alleles in black women compared to the women of mixed-
ancestry.
Conclusion: This is the first study on the role of Fas and FasL polymorphisms in cervical cancer
in African populations. Our results suggest that these SNPs are not associated with cervical cancer
in these populations. The allele frequencies of the three SNPs differed markedly between the
indigenous African black and mixed-ancestry populations.
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Background
Cervical cancer is caused by persistent infection with spe-
cific types of human papillomavirus (HPV). During their
life-time, many women become infected with HPV but
most are able to clear the infection and only a small frac-
tion develop cervical cancer. This indicates that additional
risk factors play an important role in the development of
cervical cancer. These risk factors include host and viral
genetic factors as well as environmental and life style fac-
tors [1].
One of the most important mechanisms of the human
immune system to control viral infection is to induce
apoptosis of viral-infected cells [2]. Apoptosis is a highly
regulated process of cell suicide and depends on signals
from the cell surface death receptor Fas/CD95, which
together with Fas ligand (FasL), triggers programmed cell
death [3]. In this paper two polymorphisms in Fas (FasR-
1377G/A, FasR-670A/G) and one in FasL (FasL844T/C)
were studied in South African women with cervical cancer
compared to controls without cancer of the cervix. The sig-
nals produced by the DNA binding of transcription factors
SP1 (stimulatory protein 1) and STAT1 (signal transducer
and activator of transcription 1) are associated with tran-
scriptional activation and expression of the FasR gene.
FasR-1377 and FasR-670 are located in SP1 and STAT1
binding sites, respectively. It has been shown that the
FasR-1377A in the FasR promoter considerably reduces
SP1 binding compared to -1377G, resulting in a decrease
of Fas gene expression [4,5]. An A→G change at Fas-670
reduces the expression of the FasR, by abolishing the
Gamma interferon activation signal binding site which
results in decreased activation of induced cell death [4-6].
It has also been shown that the FasL-844C allele is associ-
ated with higher basal expression than the -844T allele
and that reduced expression of FasL inhibits the apoptotic
activity of the FasR-FasL pathway [7].
Six studies in different populations have been published
on the association of these SNPs with cervical cancer. One
investigated the FasR-670A/G polymorphism in a case-
control study in the Chinese population and reported an
association of the A allele and A/A genotype with higher
risk of developing cervical cancer [8]. The same group
showed an association of FasR-670A/A with cervical can-
cer in another case-control study [9] but did not find an
association of the FasR-1377G/A or FasL-844T/C poly-
morphisms with disease severity. Two studies, one a case
control study in a Polish group [10] the second an affected
sib-pair (ASP) study in a Swedish group [11], did not
detect an association with FasR-670A/G. Two case-control
studies, one in the Chinese [12] and the other Swedish
[13] populations, investigated the FasL-844T/C polymor-
phism. While the FasL-844C allele and C/C genotype were
associated with cervical cancer in the Chinese study, no
such effect was found in the Swedish women.
The importance of host genetic susceptibility factors for
cervical cancer development has been demonstrated by
epidemiological studies. A hereditary component of cervi-
cal tumors was detected in twin studies [14] and in a
mother-daughter family study [15]. Biological first-degree
relatives of women with cervical cancer have an increased
risk of developing cancer of the cervix compared to non-
biological relatives of women with cervical cancer [16].
Several studies addressing the association of cervical can-
cer with Fas and FasL have been published [8-13], but no
studies have been performed in African populations. We
therefore studied the association of polymorphisms in Fas
and FasL with cancer of the cervix in South African women
of black and mixed-ancestry origin.
Methods
Participants
Participants were 447 women with invasive cervical can-
cer (106 black African and 341 women of mixed-ancestry)
and 424 controls (101 black African and 323 women of
mixed-ancestry) without cancer of the cervix recruited
from hospitals or clinics in the Western Cape Province,
South Africa. The control women were selected to be rep-
resentative of the population from which the cases were
selected, specifically similar to the cases with respect to
age, ethnicity and domicile status (urban/rural), so that
case-control status would not be associated with either of
those. There were 264 (59%) urban cases and 183 (41%)
rural cases compared to 247 (58%) urban controls and
177 (42%) rural controls. The cases and controls formed
part of a study to investigate the association of oral contra-
ceptives with cervical cancer [17,18].
Clinical specimens
Blood was collected from cases and controls, following
written informed consent and stored at -80°C. The study
was approved by the University of Cape Town Research
Ethics Committee (REC REF: 075/2009). The subject
identifiers were permanently unlinked from the speci-
mens. The HIV infection status was known for 98% (n =
437) of the cases and 94% (n = 398) of the controls and
5% of the cases and 4% of the controls were positive for
HIV infections. 13% of the controls were positive for HPV
by Digene Hybrid Capture II. 14.5% of the controls in our
study had abnormal cervical cytology.
Extraction of genomic DNA
The genomic DNA was extracted using TotalNucleicAcid
Extraction kit for MagNA Pure Compact nucleic acid
extractor (Roche Diagnostics, Germany).
Determination of FasR/FasL polymorphisms
Reactions were conducted in 5 μl volumes and contained
10 ng DNA, 1.75 μl PCR MasterMix (Applied Biosystems),
0.087 μl TaqMan assay mix (FasR-1377 (rs2234767, assay
id, C_12123966_10), FasR-670 (rs1800682, assay id,BMC Research Notes 2009, 2:238 http://www.biomedcentral.com/1756-0500/2/238
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C_9578811_10), FasL844 (rs763110, custom-designed))
(Applied Biosystems) and 1.16 μl distilled water. Cycling
conditions on the ABI prism 7900 HT (Applied Biosys-
tems) were 2 minutes at 50°C, 10 minutes at 95°C, fol-
lowed by 40 cycles of 15 seconds at 92°C and one minute
at 60°C. End point fluorescence was measured immedi-
ately after cycling. Alleles were assigned using SDS 2.0
software (Applied Biosystems) [19]. The genotyping was
cross-checked by sequencing 4 samples for each polymor-
phism.
Statistical Analysis
The genotype distributions were tested for Hardy-Wein-
berg equilibrium and linkage disequilibrium in cases and
controls. Logistic regression was used to test for genotype,
allelic and haplotype associations with cervix cancer status
as well as baseline characteristics (age, ethnicity and
smoking status) and secondary outcomes such as HIV sta-
tus, abnormal cytology (Pap smear) and high risk HPV
according to Hybrid Capture II HPV Test in the control
group.
We inferred haplotypes from the two polymorphisms in
FasR, and tested their association with cervix cancer status
and between ethnicities in the controls.
Statistical analyses were done with R, the freely available
environment for graphics and statistics http://www.r-
project.org, and R packages dgc-genetics http://www-
gene.cimr.cam.ac.uk/clayton/software/ and haplo.stats
http://CRAN.R-project.org/package=haplo.stats. Broadly,
haplo.stats uses the expectation maximisation (EM) algo-
rithm, to calculate maximum likelihood estimates of
probabilities, of haplotype pairs (one paternal, one mater-
nal) for each subject, as described in Schaid et al. [20].
Results
The mean age for black cases was 43.8 yrs (SD 9.2) and for
mixed-ancestry cases it was 45.9 yrs (SD 8.1). The mean
age for black controls was 42.9 yrs (SD 9.0) and for mixed-
ancestry controls it was 45.6 yrs (SD 8.2). No significant
differences in age or HIV status were observed between
cases and controls.
The observed genotype frequencies of FasR-1377G/A,
FasR-670A/G and FasL-844T/C in the controls were all in
Hardy-Weinberg equilibrium (FasR-1377: P = 0.20, FasR-
670: P = 0.58, FasL-844: P = 0.12). The two FasR polymor-
phisms were in tight linkage disequilibrium (LD) (P <
0.05), except in the black controls (P = 0.078).
Neither the allelic, nor the genotype frequencies showed a
significant association (global P-values, 0.55, 0.12 and
0.77 for FasR-1377A, FasR-670A and FasL-844T respec-
tively) with cervical cancer status (Table 1). The haplotype
analysis for FasR-1377/-670 also did not reveal any asso-
ciation with cervical cancer in either the African black
(global P = 0.1130) (Black) or the mixed-ancestry (global
P = 0.7043) population (Table 2). The frequency of -
1377A was 12% in black cases and 9% in the black con-
trols, 21% in mixed-ancestry cases and 19% in mixed-
ancestry controls. -670A was 18% in black cases and 24%
in black controls, 36% in mixed-ancestry cases and 35%
in mixed-ancestry controls. -844C was 17% in black cases
and 14% in black controls, 34% in both mixed-ancestry
cases and controls (Table 1).
The association of three SNPs with ethnicity was investi-
gated only in the control group as the controls represent
the larger South-African population. In the control group,
all three SNPs showed significant allelic and genotype dif-
ferences (global P-values, 0.004, 0.001, < 0.001 for FasR-
1377A, FasR-670A and FasL-844T respectively) between
ethnic groups (Table 1). The FasR haplotypes (FasR-1377/
-670) also showed a significant difference (global P-value
< 0.001) between the two ethnic groups among controls
(Table 3). In the control group, both the GA and AG
(FasR-1377 and FasR-670) haplotypes were more fre-
quent in the mixed-ancestry group relative to African
black group (AG: 19% compared to 5%; GA: 35% com-
pared to 20%), while the GG haplotype was more com-
mon in blacks (71%) as compared to the mixed-ancestry
group (46%).
No significant association was found between any of the
secondary outcomes (HIV infection, abnormal cytology
(Pap smear) and hybrid capture high risk HPV) and any of
the three SNPs in the control group, adjusted for ethnicity
(results not shown here).
Discussion
Polymorphisms in the Fas or FasL genes that impair the
apoptotic signals have been associated with susceptibility
to a number of different cancers [21-27] including cervical
cancer [8-13]. We are the first to study the frequency of the
FasR-1377G/A, FasR-670A/G and FasL844T/C polymor-
phisms in an indigenous black African as well as in a
mixed-ancestry population and found no association with
cancer of the cervix. The tendencies of the odds ratios
(ORs) (FasR-1377A/A 1.37, FasR-670A/A 1.17) point
towards an increasing susceptible effect and a need for a
larger study. Although the result was not statistically sig-
nificant, there were more cases with FasR-1377A variant
compared to controls in both black African (12% vs. 9%)
and mixed-ancestry (21% vs. 19%) women. Our results
agree with the lack of association of Fas SNPs with cervical
cancer shown by three other reports [10,11,13]. The dif-
fering results between studies might be due to one or sev-
eral factors, including the difference in ethnic origin of
populations studied and the difference in sample size. TheBMC Research Notes 2009, 2:238 http://www.biomedcentral.com/1756-0500/2/238
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presence of another causative mutation in tight LD with
any of these three polymorphisms can also not be ruled
out.
We observed statistically significant allele frequency dif-
ferences for all the three Fas SNPs between ethnic groups
in the control women. For FasR-1377G/A, the A allele fre-
quency was 9% in the black Africans and 19% in women
of mixed-ancestry, which were both markedly lower than
the frequency in other populations, such as the 43% and
31% in Taiwanese and Chinese populations, respectively
[8,12]. The FasR-670A allele frequency was 24% in black
Africans and 35% in women of mixed-ancestry. This is
again lower than the average of 53% for populations from
Europe, Australasia and Asia [4,8,10,28,29]. The fre-
quency of the FasL-844C alleles was 14% in black women
and 34% in women of mixed-ancestry, which are very low
compared to the 69% and 71% in the Chinese and Swed-
ish populations respectively [12,13]. The unusually low
frequency of the Fas and FasL alleles in the African popu-
lation could contribute to a lower power to detect an asso-
ciation in the present study.
The FasR-1377G/A and FasR-670A/G SNPs are in tight LD
in our population. Both the AG and GA haplotypes were
significantly more frequent in women of mixed-ancestry
compared to GG, the most common haplotype, which
was observed at a higher frequency in black women (Table
3).
Table 1: Counts (n), frequencies (%) and association statistics for genotypes and minor-alleles (FasR-1377G/A, FasR-670A/G, FasL-
844T/C).
Black Mixed-ancestry Genotype-cervical cancer association, 
adjusted for ethnicity
Genotype-ethnic association, in 
controls only
Cases Controls Cases Controls
Genotypes n (%) n (%) n (%) n (%) P-value OR (95% CI) P-value OR (95% CI)
FASR-1377 G→A
GG 74 (77) 75 (83) 186 (64) 196 (66) - 1 - 1
AG 21 (22) 14 (16) 87 (30) 86 (29) 0.428 1.14 (0.83-1.58) 0.007 0.43 (0.22-0.77)
AA 1 (1) 1 (1) 17 (6) 13 (4) 0.391 1.37 (0.67-2.87) 0.130 0.20 (0.01-1.04)
A allele 23 (12) 16 (9) 121 (21) 112 (19) 0.275 1.15 (0.89-1.49) 0.003 0.43 (0.24-0.72)
FASR-670 A→G
GG 67 (65) 54 (55) 147 (44) 136 (42) - 1 - 1
AG 35 (34) 43 (43) 132 (40) 146 (45) 0.099 0.79 (0.59-1.05) 0.207 0.74 (0.46-1.18)
AA 1 (1) 2 (2) 53 (16) 39 (12) 0.492 1.17 (0.74-1.87) 0.006 0.13 (0.02-0.44)
A allele 37 (18) 47 (24) 238 (36) 224 (35) 0.778 0.97 (0.79-1.19) 0.003 0.57 (0.39-0.82)
FASL -844 T→C
TT 70 (68) 74 (74) 143 (44) 139 (44) - 1 - 1
CT 31 (30) 23 (23) 144 (44) 136 (43) 0.515 1.1 (0.82-1.48) < 0.001 0.32 (0.18-0.53)
CC 2 (2) 3 (3) 40 (12) 40 (13) 0.929 0.98 (0.61-1.57) 0.001 0.14 (0.03-0.41)
C allele 35 (17) 29 (14) 224 (34) 216 (34) 0.797 1.03 (0.83-1.27) < 0.001 0.34 (0.22-0.51)
P-values and OR (95% confidence intervals) are for test of genotype or additive allelic association with cervix cancer risk, adjusted for ethnicity, and 
for genotype/additive association with ethnicity in controls. For genotypes, P-values next to genotype names are for joint model, others are for ORs 
of specific genotype compared to reference genotype, indicated with OR = 1. ORs for alleles are the odds for an additional copy of that allele. ORs 
for genotype-ethnicity association (in controls only) are odds of genotype/allele in black compared to odds of genotype/allele in individuals of 
mixed-ancestry.
Cases = Women with cancer of the cervix, Controls = Women without cancer of the cervix.
Table 2: Inferred frequencies, %, for FasR-1377 and FasR 670 haplotypes and odds ratios for risk of cervix cancer.
Black Mixed-ancestry
Haplotype Cases Controls OR (95% CI) Cases Controls OR (95% CI)
GG 70 71 1 44 46 1
GA 18 20 0.8 (0.45-1.43) 36 35 1.08 (0.85-1.38)
AG 12 5 2.07 (0.87-4.93) 20 19 1.12 (0.83-1.52)
AA 0 4 - 0 0 -
Odds ratios (95% confidence intervals) are for testing FasR-1377 and FasR-670 haplotype association with risk of cervix cancer versus reference 
haplotype GG, stratified by ethnicity. Global P = 0.1130 (Black) and 0.7043 (Mixed ancestry).BMC Research Notes 2009, 2:238 http://www.biomedcentral.com/1756-0500/2/238
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Conclusion
Our study did not show a significant association of the
FasR-1377G/A, FasR-670A/G and FasL-844T/C polymor-
phisms with cervical cancer. A statistically significant dif-
ference was found in the allele and genotypes frequencies
of the three SNPs between women of black African and
mixed-ancestry in the control population.
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